Cargando…
Improved predictability of pancreatic ductal adenocarcinoma diagnosis using a blood immune cell biomarker panel developed from bulk mRNA sequencing and single-cell RNA-sequencing
BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) remains a devastating cancer due to its poor survival rate, early detection, and resectability. This study aimed to determine the peripheral blood mononuclear cell (PBMC) immune biomarkers in patients with PDAC and investigate the PDAC-specific per...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10361912/ https://www.ncbi.nlm.nih.gov/pubmed/37165046 http://dx.doi.org/10.1007/s00262-023-03458-8 |
_version_ | 1785076310659301376 |
---|---|
author | Jang, Sung Ill Lee, Hyung Keun Chang, Eun-Ju Kim, Somi Kim, So Young Hong, In Young Kim, Jong Kyoung Lee, Hye Sun Yang, Juyeon Cho, Jae Hee Lee, Dong Ki |
author_facet | Jang, Sung Ill Lee, Hyung Keun Chang, Eun-Ju Kim, Somi Kim, So Young Hong, In Young Kim, Jong Kyoung Lee, Hye Sun Yang, Juyeon Cho, Jae Hee Lee, Dong Ki |
author_sort | Jang, Sung Ill |
collection | PubMed |
description | BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) remains a devastating cancer due to its poor survival rate, early detection, and resectability. This study aimed to determine the peripheral blood mononuclear cell (PBMC) immune biomarkers in patients with PDAC and investigate the PDAC-specific peripheral blood biomarker panel and validate its clinical performance. METHODS: In this prospective, blinded, case–control study, a biomarker panel formula was generated using a development cohort—including healthy controls, patients at high risk of PDAC, and patients with benign pancreatic disease, PDAC, or other gastrointestinal malignancies—and its diagnostic performance was verified using a validation cohort, including patients with ≥ 1 lesion suspected as PDAC on computed tomography (CT). RESULTS: RNA-sequencing of PBMCs from patients with PDAC identified three novel immune cell markers, IL-7R, PLD4, and ID3, as specific markers for PDAC. Regarding the diagnostic performance of the regression formula for the three biomarker panels, the sensitivity, specificity, positive predictive value, negative predictive value, and accuracy were 84.0%, 78.8%, 47.2%, 95.6%, and 79.8%, respectively. Based on the formula scores for the biomarker panel, the false-negative rate (FNR) of the biomarkers was 8% (95% confidence interval [CI] 3.0–13.0), which was significantly lower than that based on CT in the validation cohort (29.2%, 95% CI 20.8–37.6). CONCLUSIONS: The regression formula constructed using three PBMC biomarkers is an inexpensive, rapid, and convenient method that shows clinically useful performance for the diagnosis of PDAC. It aids diagnoses and differential diagnoses of PDAC from pancreatic disease by lowering the FNR compared to CT. Clinical trial registration Clinical Research Information Service, KCT0004614 (08 January 2020). SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00262-023-03458-8. |
format | Online Article Text |
id | pubmed-10361912 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-103619122023-07-23 Improved predictability of pancreatic ductal adenocarcinoma diagnosis using a blood immune cell biomarker panel developed from bulk mRNA sequencing and single-cell RNA-sequencing Jang, Sung Ill Lee, Hyung Keun Chang, Eun-Ju Kim, Somi Kim, So Young Hong, In Young Kim, Jong Kyoung Lee, Hye Sun Yang, Juyeon Cho, Jae Hee Lee, Dong Ki Cancer Immunol Immunother Research BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) remains a devastating cancer due to its poor survival rate, early detection, and resectability. This study aimed to determine the peripheral blood mononuclear cell (PBMC) immune biomarkers in patients with PDAC and investigate the PDAC-specific peripheral blood biomarker panel and validate its clinical performance. METHODS: In this prospective, blinded, case–control study, a biomarker panel formula was generated using a development cohort—including healthy controls, patients at high risk of PDAC, and patients with benign pancreatic disease, PDAC, or other gastrointestinal malignancies—and its diagnostic performance was verified using a validation cohort, including patients with ≥ 1 lesion suspected as PDAC on computed tomography (CT). RESULTS: RNA-sequencing of PBMCs from patients with PDAC identified three novel immune cell markers, IL-7R, PLD4, and ID3, as specific markers for PDAC. Regarding the diagnostic performance of the regression formula for the three biomarker panels, the sensitivity, specificity, positive predictive value, negative predictive value, and accuracy were 84.0%, 78.8%, 47.2%, 95.6%, and 79.8%, respectively. Based on the formula scores for the biomarker panel, the false-negative rate (FNR) of the biomarkers was 8% (95% confidence interval [CI] 3.0–13.0), which was significantly lower than that based on CT in the validation cohort (29.2%, 95% CI 20.8–37.6). CONCLUSIONS: The regression formula constructed using three PBMC biomarkers is an inexpensive, rapid, and convenient method that shows clinically useful performance for the diagnosis of PDAC. It aids diagnoses and differential diagnoses of PDAC from pancreatic disease by lowering the FNR compared to CT. Clinical trial registration Clinical Research Information Service, KCT0004614 (08 January 2020). SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00262-023-03458-8. Springer Berlin Heidelberg 2023-05-10 2023 /pmc/articles/PMC10361912/ /pubmed/37165046 http://dx.doi.org/10.1007/s00262-023-03458-8 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Research Jang, Sung Ill Lee, Hyung Keun Chang, Eun-Ju Kim, Somi Kim, So Young Hong, In Young Kim, Jong Kyoung Lee, Hye Sun Yang, Juyeon Cho, Jae Hee Lee, Dong Ki Improved predictability of pancreatic ductal adenocarcinoma diagnosis using a blood immune cell biomarker panel developed from bulk mRNA sequencing and single-cell RNA-sequencing |
title | Improved predictability of pancreatic ductal adenocarcinoma diagnosis using a blood immune cell biomarker panel developed from bulk mRNA sequencing and single-cell RNA-sequencing |
title_full | Improved predictability of pancreatic ductal adenocarcinoma diagnosis using a blood immune cell biomarker panel developed from bulk mRNA sequencing and single-cell RNA-sequencing |
title_fullStr | Improved predictability of pancreatic ductal adenocarcinoma diagnosis using a blood immune cell biomarker panel developed from bulk mRNA sequencing and single-cell RNA-sequencing |
title_full_unstemmed | Improved predictability of pancreatic ductal adenocarcinoma diagnosis using a blood immune cell biomarker panel developed from bulk mRNA sequencing and single-cell RNA-sequencing |
title_short | Improved predictability of pancreatic ductal adenocarcinoma diagnosis using a blood immune cell biomarker panel developed from bulk mRNA sequencing and single-cell RNA-sequencing |
title_sort | improved predictability of pancreatic ductal adenocarcinoma diagnosis using a blood immune cell biomarker panel developed from bulk mrna sequencing and single-cell rna-sequencing |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10361912/ https://www.ncbi.nlm.nih.gov/pubmed/37165046 http://dx.doi.org/10.1007/s00262-023-03458-8 |
work_keys_str_mv | AT jangsungill improvedpredictabilityofpancreaticductaladenocarcinomadiagnosisusingabloodimmunecellbiomarkerpaneldevelopedfrombulkmrnasequencingandsinglecellrnasequencing AT leehyungkeun improvedpredictabilityofpancreaticductaladenocarcinomadiagnosisusingabloodimmunecellbiomarkerpaneldevelopedfrombulkmrnasequencingandsinglecellrnasequencing AT changeunju improvedpredictabilityofpancreaticductaladenocarcinomadiagnosisusingabloodimmunecellbiomarkerpaneldevelopedfrombulkmrnasequencingandsinglecellrnasequencing AT kimsomi improvedpredictabilityofpancreaticductaladenocarcinomadiagnosisusingabloodimmunecellbiomarkerpaneldevelopedfrombulkmrnasequencingandsinglecellrnasequencing AT kimsoyoung improvedpredictabilityofpancreaticductaladenocarcinomadiagnosisusingabloodimmunecellbiomarkerpaneldevelopedfrombulkmrnasequencingandsinglecellrnasequencing AT honginyoung improvedpredictabilityofpancreaticductaladenocarcinomadiagnosisusingabloodimmunecellbiomarkerpaneldevelopedfrombulkmrnasequencingandsinglecellrnasequencing AT kimjongkyoung improvedpredictabilityofpancreaticductaladenocarcinomadiagnosisusingabloodimmunecellbiomarkerpaneldevelopedfrombulkmrnasequencingandsinglecellrnasequencing AT leehyesun improvedpredictabilityofpancreaticductaladenocarcinomadiagnosisusingabloodimmunecellbiomarkerpaneldevelopedfrombulkmrnasequencingandsinglecellrnasequencing AT yangjuyeon improvedpredictabilityofpancreaticductaladenocarcinomadiagnosisusingabloodimmunecellbiomarkerpaneldevelopedfrombulkmrnasequencingandsinglecellrnasequencing AT chojaehee improvedpredictabilityofpancreaticductaladenocarcinomadiagnosisusingabloodimmunecellbiomarkerpaneldevelopedfrombulkmrnasequencingandsinglecellrnasequencing AT leedongki improvedpredictabilityofpancreaticductaladenocarcinomadiagnosisusingabloodimmunecellbiomarkerpaneldevelopedfrombulkmrnasequencingandsinglecellrnasequencing |